CanSino One-Shot COVID Vaccine Accepted by WHO
publication date: May 24, 2022
Tianjin CanSino Biologics reported its novel recombinant Coronavirus vaccine, Convidecia™, was approved for Emergency Use by WHO. Convidecia is a one-shot COVID vaccine with an adenovirus type 5 vector that expresses the SARS-CoV-2 coronavirus spike protein. According to CanSinoBio, the one-shot feature and the vaccine’s storage stability between 2°C and 8°C both factored into WHO’s approval, along with its efficacy. Convidecia is approved in China and ten other countries outside the US and EU markets. It has also shown efficacy as a heterologous booster. More details....
Stock Symbols: (SHA: 688185; HK: 06185)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.